Trial Profile
A Phase I Trial Assessing Adalimumab (Humira), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Acronyms TAM-RT
- 25 Jan 2016 Status changed from recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 11 Aug 2015 New trial record